

## Sophisticated approaches to advanced RCC

Poster Session 69

Monday, 27 March  
14:00 - 15:30

**Location:** Room Copenhagen, North Hall (Level 1)

**Chairs:** J.I. Martínez Salamanca, Majadahonda (ES)  
V. Matveev, Moscow (RU)  
M.C. Mir Maresma, Cleveland (US)

**Aims and objectives of this session**

To discuss different surgical aspects of nephrectomy for advanced RCC.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 910 **Renal tumor management in Scandinavia: A multi-institutional survey**  
**By:** Nisen H.<sup>1</sup>, Jarvinen P.<sup>1</sup>, Lund L.<sup>2</sup>, Ljungberg B.<sup>3</sup>, Kromann-Andersen B.<sup>4</sup>, Gudmundsson E.<sup>5</sup>, Sundqvist P.<sup>6</sup>, Fovaeus M.<sup>7</sup>, Nilsen F.<sup>8</sup>, Beisland C.<sup>9</sup>  
**Institutes:**<sup>1</sup>HUCH Helsinki University Central Hospital, Dept. of Urology, Helsinki, Finland, <sup>2</sup>Odense University Hospital, Dept. of Urology, Odense, Denmark, <sup>3</sup>Umeå University, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden, <sup>4</sup>Herlev University Hospital, Dept. of Urology, Copenhagen, Denmark, <sup>5</sup>Landspítali, Dept. of Urology, Reykjavik, Iceland, <sup>6</sup>Örebro University Hospital, Dept. of Urology, Örebro, Sweden, <sup>7</sup>Sahlgrenska University Hospital, Dept. of Urology, Gothenburg, Sweden, <sup>8</sup>Akershus University Hospital, Dept. of Urology, Oslo, Norway, <sup>9</sup>Haukelan University Hospital, Dept. of Urology, Bergen, Norway
- 911 **Multicenter analysis of oncologic and renal functional outcomes of radical and partial nephrectomy in stage II renal cell carcinoma**  
**By:** Hamilton Z.<sup>1</sup>, Correa A.<sup>2</sup>, Larcher A.<sup>4</sup>, Khene Z.<sup>3</sup>, Fero K.<sup>1</sup>, Han D.<sup>1</sup>, Bloch A.<sup>1</sup>, Field C.<sup>1</sup>, Peyronnet B.<sup>3</sup>, Capitanio U.<sup>4</sup>, Montorsi F.<sup>4</sup>, Bensalah K.<sup>3</sup>, Uzzo R.<sup>2</sup>, Derweesh I.<sup>1</sup>  
**Institutes:**<sup>1</sup>Moore's Cancer Center, Dept. of Urology, La Jolla, United States of America, <sup>2</sup>Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, <sup>3</sup>University of Rennes, Dept. of Urology, Rennes, France, <sup>4</sup>San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy
- 912 **Partial versus radical nephrectomy in patients with renal cell carcinoma and renal or caval thrombus: Oncological and functional outcomes from an individual matched cohort analysis**  
**By:** Marra G.<sup>1</sup>, Gontero P.<sup>1</sup>, Brattoli M.<sup>1</sup>, Filippini C.<sup>2</sup>, Linares Espinos E.<sup>3</sup>, Capitanio U.<sup>4</sup>, Montorsi F.<sup>4</sup>, Daneshmand S.<sup>6</sup>, Huang W.C.<sup>7</sup>, Martínez-Salamanca J.I.<sup>8</sup>, McKiernan J.M.<sup>9</sup>, Scherr D.S.<sup>10</sup>, Zigeuner R.<sup>11</sup>, Libertino J.A.<sup>5</sup>  
**Institutes:**<sup>1</sup>San Giovanni Battista Hospital, Dept. of Urology, Turin, Italy, <sup>2</sup>San Giovanni Battista Hospital, Dept. of Urology, Turin, Italy, <sup>3</sup>Hospital Universitario Puerta De Hierro-Madrid, Dept. of Urology, Madrid, Spain, <sup>4</sup>San Raffaele Hospital, Dept. of Urology, Milan, Italy, <sup>5</sup>Lahey Clinic, Dept. of Urology, Burlington, United States of America, <sup>6</sup>USC/Norris Comprehensive Cancer Center, Dept. of Urology, Los Angeles, United States of America, <sup>7</sup>University School of Medicine, Dept. of Urology, New York, United States of America, <sup>8</sup>Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autónoma de Madrid, Dept. of Urology, Madrid, Spain, <sup>9</sup>Columbia University College of Physicians and Surgeons, Dept. of Urology, New York, United States of America, <sup>10</sup>Weill Cornell Medical Center, Dept. of Urology, New York, United States of America, <sup>11</sup>Medical University of Graz, Dept. of Urology, Graz, Austria
- 913 **Comparison of different surgical approaches for the management of renal cell carcinoma invading the renal vein**  
**By:** Hanna N., Ingham M., Seisen T., Chang S.  
**Institutes:**Brigham and Women's Hospital, Dept. of Urology, Boston, United States of America

- 914 **Robot assisted radical nephrectomy and inferior vena cava thrombectomy: Surgical technique, perioperative and oncologic outcomes**  
**By:** Simone G.<sup>1</sup>, Hatcher D.<sup>2</sup>, Ferriero M.<sup>1</sup>, Minisola F.<sup>1</sup>, Misuraca L.<sup>1</sup>, Tuderti G.<sup>1</sup>, Guaglianone S.<sup>1</sup>, De Castro Abreu A.L.<sup>2</sup>, Aron M.<sup>2</sup>, Desai M.<sup>2</sup>, Gill I.S.<sup>2</sup>, Gallucci M.<sup>1</sup>  
**Institutes:**<sup>1</sup>Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, <sup>2</sup>Keck School of Medicine, University of Southern California, Institute of Urology, Los Angeles, United States of America
- 915 **Robotic versus open inferior Vena cava (IVC) tumor thrombectomy: The initial comparison**  
**By:** Chopra S., Loh-Doyle J., Cai J., Daneshman S., Djaladat H., Desai M., Gallucci M., Gill I.S.  
**Institutes:**Usc Institute of Urology, Dept. of Urology, Los Angeles, United States of America
- 916 **Comparison between laparoendoscopic single site nephrectomy and conventional laparoscopic nephrectomy: A randomized control single institution experience**  
**By:** Eltemamy M., Abdel Hakim M., El-Feel A., Abdel Wahab M., Abdallah A., Elshafei A., Omar A.-R.  
**Institutes:**Cairo University, Dept. of Urology, Cairo, Egypt
- 917 **Impact of intraoperative blood transfusions on survival after surgery for renal cell carcinoma**  
**By:** La Croce G., Muttin F., Moschini M., Larcher A., Dell'Oglio P., Nini A., Ripa F., Cianflone F., Di Trapani E., Carenci C., Dehò F., Montorsi F., Bertini R., Capitano U.  
**Institutes:**IRCCS Ospedale San Raffaele, Urological Research Institute, Unit of Urology, Division of Oncology, Milan, Italy
- 918 **The efficacy of neoadjuvant targeted therapy in treatment of localized RCC**  
**By:** Voylenko O., Vitruk I., Stakhovskiy O., Kononenko O., Pikul M., Stakhovsky E.  
**Institutes:**National Cancer Institute, Dept. of Plastic and Reconstructive Oncological Urology, Kiev, Ukraine
- 919 **Clinical benefit of presurgical axitinib therapy in renal cell carcinoma patients with thrombus extending to inferior vena cava**  
**By:** Tanaka Y., Hashimoto Y., Hatakeyama S., Hosogoe S., Noro D., Oikawa M., Tanaka T., Narita T., Hagiwara K., Tobisawa Y., Yamamoto H., Yoneyama T., Yoneyama T., Koie T., Ohyama C.  
**Institutes:**Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan
- 920 **Phase II study of axitinib for downstaging cT2a to cT1 renal tumors for allowing partial nephrectomy (AXIPAN)**  
**By:** Lebacle C.<sup>1</sup>, Bernhard J.C.<sup>2</sup>, Bensalah K.<sup>3</sup>, Baumert H.<sup>4</sup>, Lang H.<sup>5</sup>, Jacqmin D.<sup>5</sup>, Duclos B.<sup>6</sup>, Ravaud A.<sup>7</sup>, Laguerre B.<sup>8</sup>, Albiges L.<sup>9</sup>, Arnoux A.<sup>10</sup>, Escudier B.<sup>9</sup>, Patard J.J.<sup>1</sup>  
**Institutes:**<sup>1</sup>Bicêtre University Hospital, Dept. of Urology, Le Kremlin-Bicêtre, France, <sup>2</sup>Pellegrin Hospital, Dept. of Urology, Bordeaux, France, <sup>3</sup>Pontchaillou University Hospital, Dept. of Urology, Rennes, France, <sup>4</sup>Saint-Joseph Hospital, Dept. of Urology, Paris, France, <sup>5</sup>Hôpitaux Universitaires De Strasbourg, Nouvel Hôpital Civil, Dept. of Urology, Strasbourg, France, <sup>6</sup>Hôpitaux Universitaires De Strasbourg, Hôpital Hautepierre, Dept. of Oncology, Strasbourg, France, <sup>7</sup>Saint-André Hospital, University Hospital, CHU Bordeaux, Dept. of Medical Oncology, Bordeaux, France, <sup>8</sup>Eugène Marquis Center, Dept. of Oncology, Rennes, France, <sup>9</sup>Gustave Roussy Université Paris-Saclay, Dept. of Medicine, Villejuif, France, <sup>10</sup>Bicetre University Hospital, Dept. of Statistics, Le Kremlin-Bicêtre, France
- 921 **Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer**  
**By:** Szabados B.<sup>1</sup>, Gomez De Liano Lista A.<sup>1</sup>, Wimalasingham A.<sup>1</sup>, De Bruijn R.<sup>2</sup>, Haanen J.<sup>3</sup>, Blank C.<sup>3</sup>, Hall P.<sup>4</sup>, Staehler M.<sup>6</sup>, Chowdhury S.<sup>5</sup>, Hopkins T.<sup>4</sup>, Powles T.<sup>4</sup>, Bex A.<sup>2</sup>  
**Institutes:**<sup>1</sup>Barts Health Nhs Trust St Bartholomew's Hospital, Dept. of Oncology, London, United Kingdom, <sup>2</sup>The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, <sup>3</sup>The Netherlands Cancer Institute, Dept. of Oncology, Amsterdam, The Netherlands, <sup>4</sup>Barts Health NHS Trust St Bartholomew's Hospital, Dept. of Oncology, London, United Kingdom, <sup>5</sup>Guy's, King's and St Thomas' Hospitals, Dept. of Oncology, London, United Kingdom, <sup>6</sup>University Hospital Munich-

Grosshadern, Dept. of Urology, Munich, Germany

922

**S-TRAC adjuvant sunitinib phase 3 trial in patients with high risk renal cell carcinoma: Subgroups analyses by risk factors**

**By:** Stahler M.<sup>1</sup>, Patard J.-J.<sup>2</sup>, Pantuck A.<sup>3</sup>, Ravaud A.<sup>4</sup>, Motzer R.<sup>5</sup>, Pandha H.<sup>6</sup>, George D.<sup>7</sup>, Chang Y.-H.<sup>8</sup>, Escudier B.<sup>9</sup>, Donskov F.<sup>10</sup>, Magheli A.<sup>11</sup>, Carteni G.<sup>12</sup>, Laguerre B.<sup>13</sup>, Tomczak P.<sup>14</sup>, Breza J.<sup>15</sup>, Gerletti P.<sup>16</sup>, Lechuga M.<sup>16</sup>, Lin X.<sup>17</sup>, Casey M.<sup>18</sup>, Patel A.<sup>19</sup>

**Institutes:**<sup>1</sup>University Hospital of Munich, Dept. of Urology, Munich, Germany, <sup>2</sup>Bicêtre Hospital, Paris-Saclay University, Dept. of Urology, Le Kremlin Bicêtre, France, <sup>3</sup>Ronald Reagan UCLA Medical Center, Dept. of Urology, Los Angeles, Ca, United States of America, <sup>4</sup>Bordeaux University Hospital, Dept. of Medical Oncology, Bordeaux, France, <sup>5</sup>Memorial Sloan Kettering Cancer Center, Dept. of Oncology, New York, United States of America, <sup>6</sup>University of Surrey, Dept. of Clinical and Experimental Medicine, Surrey, United Kingdom, <sup>7</sup>Duke Cancer Center, Dept. of Oncology, Durham, United States of America, <sup>8</sup>Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, <sup>9</sup>Institut Gustave Roussy, Dept. of Medical Oncology, Villejuif, France, <sup>10</sup>Aarhus University Hospital, Dept. of Oncology, Aarhus, Denmark, <sup>11</sup>Charité Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, <sup>12</sup>Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Dept. of Oncology and Urology, Naples, Italy, <sup>13</sup>Centre Eugene Marquis, Dept. of Medical Oncology, Rennes, France, <sup>14</sup>Klinika Onkologii Oddzial Chemioterapii, Dept. of Oncology, Poznan, Poland, <sup>15</sup>Slovak Medical University In Bratislava, Dept. of Urology, Bratislava, Slovakia, <sup>16</sup>Pfizer S.r.L, Dept. of Oncology, Milan, Italy, <sup>17</sup>Pfizer Inc, Dept. of Oncology, La Jolla, United States of America, <sup>18</sup>Pfizer Inc, Dept. of Oncology, New York, United States of America, <sup>19</sup>Spire Roding Hospital, Dept. of Urology, London, United Kingdom

15:15 - 15:22

**Summary**

M.C. Mir Maresma, Cleveland (US)